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The age-related accumulation of mitochondrial DNAmutations has the potential to impair organ function and contribute to disease. In support of
this hypothesis, accelerated mitochondrial mutagenesis is pathogenic in the mouse heart, and there is an increase in myocyte apoptosis. The current
study sought to identify functional alterations in cell death signaling via mitochondria. Of particular interest is the mitochondrial permeability
transition pore, opening of which can initiate cell death, while pore inhibition is protective. Here, we show that mitochondria from transgenic mice
that developmitochondrial DNAmutations have amarked inhibition of calcium-induced pore opening. Temporally, inhibited pore opening coincides
with disease. Pore inhibition also correlates with an increase in Bcl-2 protein integrated into the mitochondrial membrane. We hypothesized that pore
inhibition was mediated by mitochondrial Bcl-2. To test this hypothesis, we treated isolated mitochondria with Bcl-2 antagonistic peptides (derived
from the BH3 domain of Bax or Bid). These peptides released the inhibition to pore opening. The data are consistent with a Bcl-2-mediated inhibition
of pore opening. Thus, mitochondrial DNAmutations induce an adaptive–protective response in the heart that inhibits opening of the mitochondrial
permeability pore.
© 2006 Elsevier B.V. All rights reserved.Keywords: Apoptosis; mtDNA; Bcl-2; Mitochondria; Calcium; Permeability transition pore1. Introduction
Mitochondria contain their own genome which accumulates
mutations with age [1]. Further, levels of mitochondrial DNA
mutations are elevated in disease states, including heart disease
[2,3]. This correlative information suggests that mitochondrial
DNA mutations may contribute to senescence and disease. In
support of this hypothesis, accelerated mutagenesis of the mito-
chondrial genome in the heart leads to heart disease [4].
Interestingly, mitochondrial respiratory function remains in-
tact, as would be expected given the low level of mutations [4].
Further, oxidative stress does not increase, contrary to the hy-
pothesized vicious cycle [5]. One proposed mechanism by which
mitochondrial DNA mutations may contribute to disease is
through apoptosis.Mitochondria regulate the intrinsic pathway of
apoptosis through the release of apoptogenic factors, for instance⁎ Corresponding author. Tel.: +1 314 977 8896; fax: +1 314 977 8717.
E-mail address: zassenp@slu.edu (H.P. Zassenhaus).
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doi:10.1016/j.bbabio.2006.04.014cytochrome c [6]. Cytochrome c can be released through opening
of the mitochondrial permeability transition pore [7]. The pore is
highly regulated, [8,9] pore opening can trigger cell death, [10]
and inhibition of pore opening can prevent cell death [11].
To study the effects of accumulating mitochondrial DNA
mutations, we previously generated a transgenic mouse model
[4]. Transgenic mice expressed a proofreading-deficient mito-
chondrial DNA polymerase in the heart, and accumulated mito-
chondrial DNA mutations at an accelerated rate. These mice
developed heart disease and a prominent aspect of the pathology
was increased cell death, including increased release of mito-
chondrial cytochrome c [12].
Further, we observed increased Bcl-2 levels in hearts of trans-
genic mice [5]. The Bcl-2 family proteins all share at least one
Bcl-2 homology domain (BH-domain). Antiapoptotic members
have BH domains 1–4, while proapoptotic members contain BH
1–3. The “BH3-only” family members are unrelated except at the
BH3 domain (for review, see Ref. [13]). Bcl-XL and Bcl-2 inhibit
pore opening induced by calcium, [14,15] and this function is
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there is a balance of pro- and antiapoptotic Bcl-2 family members
at the mitochondrial membrane regulating pore opening and
cytochrome c release.
The confluence of apoptosis and Bcl-2 upregulation in mice
with mitochondrial lesions led us to study the function of the
mitochondrial permeability transition pore. Specifically, we ex-
amined calcium-induced pore opening, mitochondrial calcium
uptake, and Bcl-2-mediated pore inhibition.Fig. 1. Fluorescence measurements of mitochondrial respiratory function.
(Panel A) Mitochondria (50 μg/mL) were suspended in respiration buffer, and
respiratory function was assayed using the lipophilic cation JC-1. As the
transmembrane potential increases upon charging with substrates of complex I
(Sub I) or II (Sub II), so does the ratio of emitted fluorescence (590 nm/530 nm).
The complex I inhibitor rotenone and the complex IV inhibitor cyanide (KCN)
arrest respiration, and the transmembrane potential quickly dissipates. (Panel B)
Mitochondria were charged with succinate and pore opening was activated by
calcium (25 μM; curve 1; solid square). Pore opening and loss of potential can be
prevented (curve 2; open circle) or reversed (curve 3; open triangle) by the pore
inhibitor cyclosporin A in the presence of ADP. The actual JC-1 ratio was
converted as in Materials and methods to facilitate comparison. In Panel B, the
average ratio at calcium addition for the 3 runs was 5.42±1.79.2. Materials and methods
2.1. Animals
The transgenic mice used in this study express a proofreading-deficient
mitochondrial DNA polymerase under direction of the heart-specific a-myosin
heavy chain promoter and have been described [4]. They were maintained as
two independent lines, hemizygous animals were studied and always compared
to wildtype littermate controls. No differences in results were noted between the
two transgenic lines. All procedures were approved by the Institutional Animal
Care and Use Committee.
2.2. Mitochondrial isolation
Cardiac mitochondria were isolated by differential centrifugation [18] in
isolation buffer (210 mM mannitol, 70 mM sucrose, 1 mM EGTA, 5 mM 4-
morpholenepropanesulfonic acid (MOPS), 0.5% fatty acid-free BSA, pH 7.2
with potassium hydroxide). The pellet was then washed and mitochondrial ADP
was depleted by treatment for 5 min at 30 °C with 2 mM pyrophosphate in
isolation buffer [19]. Mitochondria were washed twice with resuspension buffer
(250 mM sucrose, 0.1 mM EGTA–tris, 10 mM Tris–HCl, pH 7.4), and then
resuspended at approximately 20 mg of mitochondrial protein/mL (proteins by
BCA). Hearts from multiple animals (usually 4–6) were processed together to
ensure adequate mitochondria for each experiment. In the figure legends, “n”
refers to the number of independent mitochondrial preparations tested.
2.3. Respiration
Mitochondria (50 μg) were added to 1 mL respiration buffer (250 mM sucrose,
10 mM phosphoric acid–tris, 5 μM EGTA–tris, 10 mM MOPS–tris, pH 7.3) that
contained 250 nM JC-1 (Molecular Probes, Eugene, OR). Complex I activity was
stimulated by the addition of 5 mM pyruvate, 5 mMmalate, and 5 mM glutamate
(pH 7.5), and complex II was stimulated by 5 mM succinate (pH 8). Rotenone was
used to inhibit complex I at 2 μM, potassium cyanide was used to inhibit complex
IV at 2 mM, and oligomycin was used to inhibit complex V at 0.25 μg/mL.
Fluorescence of JC-1 was monitored every minute using an excitation wavelength
(λex) of 490 nm and emission wavelength (λem) of 530 nm, followed immediately
by a reading at λex 490 nm, λem 590 nm. The delay between the readings was
approximately 4 s. The readings for each time point were converted to fluorescence
ratio by dividing the signal at λem 590 nm by the signal at λem 530 nm.
2.4. Pore opening, cuvette
Mitochondria (50 μg/mL final) were added to respiration buffer that
contained 250 nM JC-1, 2 μM rotenone, 0.25 μg/mL oligomycin, and 5 mM
succinate. JC-1 fluorescence readings were taken every minute as above, and the
fluorescent ratio was converted into normalized ratio using time zero as 0% and
the time point immediately before the addition of calcium as 100%. The ratio at
time zero was similar to the value obtained after respiration inhibition by cyanide.
The ratio just before calcium addition varied from run-to-run and experiment-to-
experiment, and is indicated in the figure legends. The addition of calcium is
indicated in the figures. Calcium stocks were prepared fresh daily.
Calcium is known to induce a transient depolarization in mitochondria due to
its electrophoretic accumulation. This transient depolarization was seen in multipletraces (not shown) as a reversible decrease in the normalized ratio of JC1 lasting for
1 to 4min. This decreasewas not seen in all experiments, and is thus not apparent in
Figs. 1 and 2.
2.5. Pore opening, 96-well plate
For some replicates, assays were performed in microtiter plates. Conditions
were as above, except that the final volumewas 200μL.Mitochondrial suspensions
were prepared and then aliquoted into a black 96-well plate and fluorescence
readings taken everyminute. At the start of the experiment and after every addition,
the plate was shaken (orbital) for 5 s. Because the reactions were prepared in bulk,
aliquoted, and shaken before the first time point, the fluorescence reading at “time
zero” was slightly delayed compared to runs using cuvettes. Another minor dif-
ference was that readings were taken at λex 485 nm, λem 535 and 595 nm, and the
delay between reading the λem at 535 nm and 595 nm was about 15 s. Conditions
were otherwise the same.
2.6. Western blots
The protein levels of Bcl-2 were determined by Western blot of 50 μg
mitochondrial protein (antibody from Santa Cruz, CA). Equal loading was
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from Calbiochem, La Jolla, CA). Primary antibody was detected by horseradish
peroxidase-conjugated secondary antibodies (Jackson Immunoresearch, West
Grove, PA), followed by detection by ECL-plus (Amersham, Piscataway, NJ).
2.7. BH3 peptides
Peptides were obtained from Research Genetics (now Invitrogen, Carlsbad,
CA) corresponding to the BH3 domain of human Bax and human Bid proteins,
see Fig. 6 for sequences. These peptides were resuspended in degassed dH2O
and stored at −20 °C. Peptide was added to the respiration buffer before mito-
chondria, and the rest of the assay was identical to that described above.2.8. Calcium uptake
Calcium uptake was measured in respiration buffer with 5 mM succinate, as
described [20]. Calcium concentration was obtained using the binding constant
and maximal fluorescence (Fmax) values obtained by the double-reciprocal plot
of 1/fluorescence versus 1/[calcium] in assay mix without mitochondria. The
binding constant of Calcium Green 5N was determined to be 4.8 μM which is
close to the expected value (14 μM; Molecular Probes, Eugene, OR).
2.9. Statistics
Comparisons are expressed as mean±S.E.M., and significant differences
determined using two-tailed Student's t test except in experiments using BH3
peptides where multiple comparisons were possible. Then, ANOVA was used
with Bonferroni post hoc correction, significance defined at Pb0.05.
3. Results
3.1. Transmembrane potential
In mice with mitochondrial DNA mutations we see cy-
tochrome c release and cell death [12] and we hypothesized that
altered function of the mitochondrial permeability transition
pore may be the cause. Thus, we assessed the function of the
pore. First, we validated our method of measuring transmem-
brane potential. Fig. 1A demonstrates mitochondrial respirato-
ry function using the lipophilic cation JC-1 as an indicator of
transmembrane charge. When mitochondrial respiration was
initiated by the addition of NADH-generating substrates (com-
plex I substrates; Sub I), the emitted fluorescence from JC-1
changed, such that the 590 nm emission increased and the
530 nm emission decreased, graphed as the ratio of 590 to
530 nm emission. These changes are due to the membrane
potential-driven accumulation of the dye in the mitochondrial
matrix which forms J-aggregates (fluorescence emission at
590 nm) and the resultant depletion of the monomeric form
(fluorescence emission at 530 nm) [21]. This fluorescence
change was reversed upon inhibition of complex I with rote-
none. Regeneration of the potential using the complex II sub-
strate succinate (Sub II) again resulted in J-aggregate formation,
which was reversed by inhibiting electron transport downstream
of complex II by potassium cyanide inhibition of complex IV.
Thus, JC-1 tracks the mitochondrial transmembrane potential in
this system.Fig. 2. Mitochondrial pore function from mice with mitochondrial DNA
mutations. (Panel A) At low calcium concentrations (25 μM; 500 nmol/mg
mitochondrial protein), control mitochondria (CT) undergo pore opening while
mitochondria from transgenic mice (TG) are protected. Concentration depen-
dence studies (not shown) demonstrated that the optimal difference was at 25 μM
calcium, and decreased with higher calcium. The JC-1 ratio at calcium addition
was 2.97 for control and 2.73 for transgenic. (Panel B) At 100 μM calcium
(2000 nmol/mg mitochondrial protein), both control (CT) and transgenic (TG)
mitochondria undergo similar, and maximal pore opening. The JC-1 ratio at
calcium additionwas 2.57 for control and 3.0 for transgenic. Note that in panels A
and B, curves reached a plateau by 5 min after the calcium pulse was delivered.
The relative charge at this time was compared between multiple independent
experiments and the results are shown in panel C. The protection in TG
mitochondria is highly significant at 25 μMcalcium and is overcome with higher
(100 μM) challenge, the average JC-1 ratio at calcium addition was 4.43±0.24.
Fig. 3. Mitochondrial pore function with age. Mitochondria (50 μg) were
challenged with 25 μM calcium as in Fig. 2. The plateau value 5 min after the
calcium pulse was compared over several mitochondrial preparations isolated
from mice of different ages. Mice aged 2–3 weeks (n=6) are considered “pre-
disease,” 4–6 weeks (n=12) is the onset of disease, measured by gross dilation,
and mice aged 7–9 weeks (n=8) have had disease for a few weeks. Note that
before onset of disease, there is no difference in pore function of CT and TG
mitochondria. At about the same time as disease onset, the difference is highly
significant, and remains significant thereafter. The average JC-1 ratio at calcium
addition was 4.61±0.21.
Fig. 5. Bcl-2 at the mitochondrial membrane. Panel A. Western blotting of
mitochondria from 6-week-old mice showed that the antiapoptotic Bcl-2 protein
was increased on the mitochondrial membrane (blot representative of at least
three independent preparations). Panel B. Western blot for VDAC was used to
confirm equal protein loading.
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Opening of the mitochondrial permeability transition pore
allows the influx of protons into mitochondria through opening of
a large, non-specific pore [22]. Pore opening thus collapses the
mitochondrial proton gradient, and can be detectedwith JC-1. JC-1
was used because it is sensitive and small amounts ofmitochondria
(such as that isolated from young mouse hearts) can be used. We
studied the function of the pore in isolated cardiac mitochondria
(Fig. 1B). Mitochondria were charged with succinate in theFig. 4. Mitochondrial calcium uptake. Mitochondria (“m”; 500 μg protein) isolated
containing succinate and 1 μM Calcium Green 5N. Fluorescence of this calcium indi
pulses (5 μM) were added every 2 min, and calcium uptake is indicated by decreasing
up into the matrix via the calcium uniporter (inhibitable with ruthenium red, an inhibit
transmembrane potential (inhibitable with cyanide).presence of rotenone and oligomycin. Oligomycin was added to
prevent the formation of ATP fromADP so the latter could be used
to inhibit the pore. Rotenone, a complex I inhibitor, was included
to ensure that charging was via complex II. Pore opening was then
triggered by calcium addition (25 μM final; arrow) and measured
as a drop in potential caused by the influx of protons through the
pore (curve 1). The drop was attributed to opening of the per-
meability transition pore because cyclosporin A (CsA) in the pre-
sence of ADP was able to prevent the calcium-induced loss of
membrane potential (curve 2). Further, the drop was not due to
inhibition of electron transport, as pore closure using CsA plus
ADP (curve 3) or calcium chelation byEGTA (not shown) resulted
in prompt restoration of the transmembrane potential.
Next, we assessed the function of the pore in mitochondria
isolated from mice with mitochondrial DNA mutations or from
littermate controls. It was expected that mitochondria from mice
with mitochondrial DNA mutations would be more sensitive to
pore opening, consistent with increased levels of apoptosis and
cytochrome c release. Interestingly, mitochondria from 5-week-
old transgenic animals actually resisted calcium-induced pore
opening (Fig. 2A). This resistance was much stronger at low
calcium concentrations (25 μM); at 100 μM calcium resistancefrom 6-week-old mice were added to 1 mL respiration buffer stirring at 30 °C,
cator was followed in real time and converted to calcium concentration. Calcium
fluorescence. Control experiments (not shown) confirmed that calcium was taken
or of the mitochondrial calcium uniporter), and that uptake was dependent upon a
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(at 5 min after calcium addition) was compared over multiple
preparations of mitochondria (Fig. 2C), the resistance at low
calciumwas highly significant, while at higher calcium, there was
no significant difference. We note that pore opening induced by
the higher concentration of calcium was still sensitive to cy-
closporin A (not shown), thus pore function is not abolished in
mice with mitochondrial DNA mutations, only inhibited.Fig. 6. Effect of Bcl-2 ligands on pore function. (Panel A) Peptides derived from the B
to Bcl-2 with interactions at the hydrophobic face. Note the conservation of hydrop
adjacent to V93 (I66 for Bax), and changing this glycine to a bulky charged residue (G
binding of the peptide to Bcl-2. (Panel B) Mitochondria were incubated with the Bax B
that calcium-induced pore opening in control mitochondria is similar to experimen
normalized pore function in transgenic mitochondria, such that 25 μM calcium ind
addition was 4.22 for control and 6.78 for transgenic. Panel C. The extent of pore ope
the absence of peptide, with Bax BH3 peptide, or with the ΔGD Bax control pe
mitochondria, while the mutantΔGD Bax has no effect. The average JC-1 ratio at cal
also restores normal pore function to mitochondria from transgenic mice, at a slight
ineffective. The average JC-1 ratio at calcium addition for experiments in Panels D a
concentration dependent in mitochondria from transgenic mice, while Bid BH3 hasWe first detected mitochondrial DNA mutations in mice at
1 week of age [4,23] followed by cytochrome c release and cell
death at three to 4 weeks-of-age [12]. Bcl-2 upregulation sim-
ilarly occurred at about 4 weeks-of-age [5]. Finally, dilation of
the hearts coincided with cell death, cytochrome c release, and
Bcl-2 upregulation [12]. Fig. 3 shows that pore dysfunction is
present by 4 weeks-of-age, similar to the onset of dilation, Bcl-2
upregulation, and cell death.H3 domains of Bcl-2 family members Bid and Bax were synthesized. These bind
hobic groups corresponding to I86, L90, and V93 of Bid. Glycine is conserved
94E Bid orΔGD Bax) disrupts the amphipathic nature of the helix and prevents
H3 peptide (40 μg/mL) starting at time zero, then challenged with calcium. Note
ts without BH3 peptide (see panels C, D, and E). However, the BH3 peptide
uced pore opening similar to control mitochondria. The JC-1 ratio at calcium
ning 5 min after calcium induction was compared across multiple experiments in
ptide. The Bax BH3 peptide (40 μg/mL) restores pore function in transgenic
cium addition was 4.73±0.18. (Panel D) Similar to Bax, the BH3 domain of Bid
ly higher concentration (100 μg/mL) and the Bid control peptide (G94E Bid) is
nd E was 3.35±0.37. (Panel E) The effect of the Bid peptide on pore opening is
no effect on control mitochondria.
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both control and transgenic hearts at 2–3 weeks of age, and in
controls this protection declines after 4 weeks of age. We have
previously shown that similarly, Bcl-2 levels are higher in 2-
week-old mice (control and transgenic pups), and decline in
control animals. Thus, the early protection may result from na-
turally elevated Bcl-2 levels in young animals during this period
of active cardiac remodeling, but this hypothesis was not speci-
fically tested here. The protection seen in mice with mitochon-
drial DNA mutations at 4 weeks of age and beyond was
investigated further. Given the unexpected finding of resisted
pore opening, we sought the molecular mechanism.
3.3. Calcium uptake
Pore opening is stimulated by calcium acting on thematrix side
of the mitochondrial inner membrane [24]. Thus, the first step in
calcium-stimulated pore opening is calcium uptake through the
calcium uniporter [8]. A defect in calcium uptakewould result in a
decreased intramitochondrial calcium level, and a decreased sig-
nal for pore opening. We used the calcium-sensitive fluorophore
Calcium Green 5N to measure calcium uptake in isolated mito-
chondria. Calcium Green 5N is excluded from mitochondria so
uptake is measured as the loss of fluorescence. Fig. 4 shows
representative traces wheremitochondria were added followed by
pulses of calcium. The initial rate of calcium uptake was the same
for mitochondria isolated from controls (339±84 pmol/s/mg) or
frommicewithmitochondrial DNAmutations (346±190 pmol/s/
mg). The amount of calcium taken up in the first minute was also
the same between control (74.4±2.5%; S.E.M.) and transgenic
(70.8±5.0%; S.E.M.) preparations. Therefore, resistance was
not the result of decreased calcium uptake, so next we assessed
whether it was due to mitochondrial Bcl-2.
3.4. Mitochondrial Bcl-2
We have previously shown that whole-heart Bcl-2 levels are
increased in transgenic mice, [5] and here we demonstrate that
Bcl-2 levels are specifically increased on the mitochondrial
membrane (Fig. 5A). Recall that Bcl-2 can inhibit pore opening
[14] and transgenic mitochondria are resistant to pore opening
(Fig. 2). Equal loading was confirmed by probing the mem-
brane with antibody against the voltage dependent anion channel
(VDAC) (Fig. 5B).
3.5. Bcl-2 inhibitory peptides
The BH3 domain of Bcl-2 family proteins (e.g. Bax and Bid)
forms an amphipathic helix, which can bind to a hydrophobic
groove in Bcl-2 [25] and reverse protection against pore opening
[26]. We designed peptides corresponding to the BH3 domain of
Bax andBid, as well as two control peptides [16,27] (Fig. 6A) and
used these to determine if the inhibition of pore opening in
mitochondria from transgenicmice could be normalizedwithBcl-
2 antagonistic peptides. The Bax BH3 peptide prevents the pro-
tection from pore opening in mitochondria from mice with
mitochondrial DNAmutations (Fig. 6B andC). Thus, the additionof a Bcl-2 ligand known to disrupt pore regulation byBcl-2 family
members [26] normalizes pore function. Pore normalization is
also achieved using a different BH3 peptide (derived from Bid;
Fig. 6D). The specificity of pore restoration was confirmed using
control peptides (see Fig. 6A for sequences). These control pep-
tides do not inhibit Bcl-2-family members [16] and likewise did
not normalize pore function (Fig. 6C and D). The reversal of
protection by the BH3 peptides was concentration dependent for
both Bid (Fig. 6E) and Bax (not shown) BH3 peptides. Thus pore
inhibition is reversed by Bcl-2 ligands and the data are consistent
with pore inhibition mediated by the increased Bcl-2 protein
present on transgenic mitochondria.
4. Discussion
Apoptotic cell death has been shown to contribute to myocyte
loss in aging, [28] as well as dilated cardiomyopathy, congestive
heart failure, [29] and myocardial infarction [30]. Increased cell
death can increase the severity of heart disease while inhibition of
the mitochondrial permeability transition pore with cyclosporin
A decreases apoptosis and heart dysfunction from ischemia–
reperfusion [31]. Similarly, mice lacking cyclophilin D, a com-
ponent of the pore and target for cyclosporin A, suffer a smaller
infarct size after cardiac ischemia–reperfusion injury [32,33].
Interestingly, the protection from cell death was to necrotic death,
triggered by calcium and/or oxidative stress [32,33].
Sublethal cardiac insults lead to protection from future insults,
called physiologic preconditioning. Preconditioning can prevent
apoptosis and decrease the severity of myocardial infarction [34].
Further, preconditioning inhibits the mitochondrial permeability
transition pore [35] and one component of preconditioning may
be mediated by Bcl-2 [36]. During aging, the loss of cardiac
myocytes [28] appears to be countered by a protective response
that may spare myocytes and preserve function. This altered ba-
lance of pro- and antiapoptotic signals is kept, in part, by the Bcl-2
family proteins [37]. Thus, regulation of the mitochondrial
permeability transition pore and cell death is important in disease
and adaptation of the heart, and may modulate cardiac disease.
Here, we have studied mice with accelerated mutagenesis of
the mitochondrial DNA in the heart. Changes present in this
model illustrate the pathogenic potential of mitochondrial DNA
mutations at levels commonly found in aging. There remain dif-
ferences, though, between mice undergoing natural aging and
mice with accelerated mitochondrial mutagenesis. For instance,
with aging comes increased oxidative damage, while we have
previously reported there is no increase in oxidative damage or
stress in these mice [5]. Further, these mice exhibit a marked
upregulation of Bcl-2 protein, while studies of aging rats have
found either significantly increased [37,38], unchanged [39], or
an apparent trend toward decreased Bcl-2 protein levels [40,41] in
24-month-old rat hearts versus 6-month-olds. It is not clear why
similar methods yielded different results, except perhaps the effort
by Centurione et al. [38], which used Wistar rats as opposed to
Fischer 344 rats in all others. It is possible that the animals used
had differing degrees of coronary artery disease. This uncertainty
illustrates the need for models of aging that can separate cause
and effect. The transgenic mice used in the present study have
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related oxidative stress or other confounding variables. This
allows for the study of the effects of mitochondrial DNA mu-
tations per se. For the same reason then, the reader should be
cautioned that this is not a model for all of aging, only for the
effects ofmitochondrial DNAmutations. Further, thesemutations
are accumulated over a period of weeks, as opposed to years in
natural aging.
In mice with mitochondrial DNA mutations, we also see an
altered apoptotic balance. Specifically, we have demonstrated
increased cytochrome c release and myocyte death, as well as an
increase in antiapoptotic Bcl-2 [5]. In the present study, we eval-
uated the function of the mitochondrial permeability transition pore
in these mice. The expectation was that increased pore opening
would explain the increase in cytochrome c release and cell death.
Instead, we found an inhibition of pore opening. Resistance was
most evident at low calcium (500 nmol/mg mitochondrial protein)
and was absent at higher calcium loads (2000 nmol/mg).
There is correlation of pore inhibitionwithBcl-2 in the literature
[14–17,42]. Further, experiments on isolated channels in the mi-
tochondrial membrane with characteristics similar to the pore
(mitochondrial megachannel) show inhibition of calcium-induced
opening [43]. Here, we showed a marked increase in Bcl-2 im-
munoreactivity on the mitochondria. Bcl-2 is known to act at the
mitochondrialmembrane to inhibit pore opening [42] though not in
all cases [44]. Of interest, previous data demonstrated elevatedBcl-
2 levels in very young control and transgenic pups (2 weeks old),
with the Bcl-2 level of control mice declining to low levels by
4 weeks of age and beyond. In contrast, mice with elevated mi-
tochondrial DNA mutations had consistently elevated levels of
Bcl-2 [5]. The sensitivity of isolated mitochondria to calcium-
induced pore opening was inhibited in both control and transgenic
mice at 2–3weeks of age, and this inhibition persisted in transgenic
mice while control mice became more sensitive (Fig. 3). This is
further correlative evidence of a role for Bcl-2 in pore inhibition.
To determine if Bcl-2 was inhibiting pore function, we
treated mitochondria isolated from mice 4 weeks of age or older
with Bcl-2 antagonistic ligands and showed restoration of pore
function. We take this to show that Bcl-2 is functional at the
level of the mitochondrial membrane, and that Bcl-2 acts to
inhibit opening of the mitochondrial permeability transition
pore in mice with mitochondrial DNA mutations. An alternate
interpretation is that a different Bcl-2 family member that also
binds the antagonistic ligands is mediating the resistance. We
have separately shown that Bcl-XL and Bfl-1 proteins are also
upregulated in transgenic mice [45]. However, the level of
Bcl-XL protein at the mitochondria is not different, suggesting
that the role of Bcl-XL in this model is non-mitochondrial. The
role of Bfl-1, including its localization, has yet to be studied in
this model, and it remains possible that Bfl-1 contributes to the
findings reported here. Interestingly, it has been shown that the
BH-3 peptides exhibit discriminatory binding preferences [46].
In our system, the concentration dependence of the Bid peptide
suggests that functional binding occurs in the range of 4.4 to
44 μM (10–100 μg/mL), consistent with the IC50 of Bid for
Bcl-2 of 6.8 μM found by Huang and colleagues. Still, we
would caution not to overinterpret this finding, as our functionalsystem is very different than their binding system, and further,
the length of BH3 peptide used was not the same. The timing,
localization, and degree of Bcl-2 upregulation, as well as the
peptide inhibitor data are consistent with the model that Bcl-2
acts at the mitochondrial membrane to inhibit pore opening in
mice with mitochondrial DNA mutations.
There remains controversy regarding the mechanism of release
of mitochondrial cytochrome c. Mice with cardiac mitochondrial
DNA mutations have increased release of cytochrome c and
increased apoptosis in the heart [12].While pore opening can cause
cytochrome c release [7,32,33], release can also occur independent
of pore opening [47,48]. Thus, the finding here that pore opening is
inhibited is not necessarily at oddswith the increased cytochrome c
release and increased cell death in these mice.
In summary, Bcl-2 is upregulated in the hearts of mice with
cardiac mitochondrial DNA mutations, and localizes to mito-
chondrial membranes. The current study provides supporting
evidence that Bcl-2 is active at the mitochondria and inhibits
opening of the permeability transition pore. Regulation of pore
opening may be important in pathogenesis in these mice, given
that cyclosporin A treatment protects mice against disease [49].
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